{"id":"NCT01646398","sponsor":"Pfizer","briefTitle":"A Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Japanese Elderly Adults Aged 65 Years Old and Older","officialTitle":"A Phase 3, Randomized, Modified Double-Blind, Active-Controlled Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine In Japanese Elderly Adults Aged 65 Years Old And Older Who Are Naive To Pneumococcal Vaccine","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-06","primaryCompletion":"2012-10","completion":"2012-10","firstPosted":"2012-07-20","resultsPosted":"2013-09-20","lastUpdate":"2013-09-20"},"enrollment":764,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Pneumococcal Vaccines","Pneumococcal Conjugate Vaccine"],"interventions":[{"type":"BIOLOGICAL","name":"13-valent pneumococcal conjugate vaccine","otherNames":["13vPnC"]},{"type":"BIOLOGICAL","name":"23-valent pneumococcal polysaccharide vaccine","otherNames":["23VPS"]}],"arms":[{"label":">= 65-year age group-13vPnC","type":"EXPERIMENTAL"},{"label":">= 65-year age group-23vPS","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the safety, tolerability and immunogenicity of a single dose of 13-valent pneumococcal conjugate vaccine compared to a single dose of 23-valent pneumococcal polysaccharide vaccine in Japanese adults aged 65 years old and older.","primaryOutcome":{"measure":"Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for 12 Common Serotypes 1 Month After Vaccination","timeFrame":"One month after vaccination","effectByArm":[{"arm":"13vPnC","deltaMin":103,"sd":null},{"arm":"23vPS","deltaMin":78,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"65 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":8,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1851088&StudyName=A%20Phase%203%20Trial%20Evaluating%20the%20Safety%2C%20Tolerability%2C%20and%20Immunogenicity%20of%20a%2013-valent%20Pneumococcal%20Conjugate%20Vaccine%20in%20Japanese%20Elde"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":382},"commonTop":["Pain (Any)","Pain (Mild)","Redness (Any)","New muscle pain","Limitation of arm movement (Any)"]}}